Boron Trichloride → HCID 118379797, compound
Reaction equation
C([O:8][CH2:9][C@@H:10]1[O:14][C:13](=[O:15])[N:12]([CH2:16][C@@H:17]2[C@H:20]([NH:21][C:22](=[O:49])/[C:23](=[N:37]\[O:38][C:39]([CH3:48])([CH3:47])[C:40]([O:42]C(C)(C)C)=[O:41])/[C:24]3[N:25]=[C:26]([NH:29]C(OC(C)(C)C)=O)[S:27][CH:28]=3)[C:19](=[O:50])[N:18]2[S:51]([OH:54])(=[O:53])=[O:52])[CH2:11]1)C1C=CC=CC=1.C(OC[C@@H]1OC(=O)N(C[C@@H]2[C@H](NC(=O)/C(=N\OC(C)(C)C(OC(C)(C)C)=O)/C3N=C(NC(OC(C)(C)C)=O)SC=3)C(=O)N2)C1)C1C=CC=CC=1.B(Cl)(Cl)Cl>C(Cl)Cl>[NH2:29][C:26]1[S:27][CH:28]=[C:24](/[C:23](=[N:37]/[O:38][C:39]([CH3:48])([CH3:47])[C:40]([OH:42])=[O:41])/[C:22]([NH:21][C@@H:20]2[C:19](=[O:50])[N:18]([S:51]([OH:54])(=[O:53])=[O:52])[C@@H:17]2[CH2:16][N:12]2[CH2:11][C@H:10]([CH2:9][OH:8])[O:14][C:13]2=[O:15])=[O:49])[N:25]=1Participants
Reactant 2
Product 1
Reagents, catalysts & solvents 1
Procedure
To a solution of tert-butyl 2-(((Z)-(2-(((2R,3S)-2-(((R)-5-((benzyloxy)methyl)-2-oxooxazolidin-3-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate (2R,3S)-2-(((R)-5-((benzyloxy)methyl)-2-oxooxazolidin-3-yl)methyl)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-4-oxoazetidine-1-sulfonate (80 mg, 0.1 mmol) in DCM (10 mL) was added BCl3 (1 M in DCM, 0.6 mL). After stirring at rt for 15 min, the reaction mixture was quenched with EtOH and concentrated in vacuo. The crude residue was purified by reverse phase prep HPLC (XSelect CSH, 30×100 mm, 5 μm, C18 column; ACN-water with 0.1% formic acid modifier, 60 mL/min), affording the title compound (1.1 mg, 2%). LCMS: m/z=549.0 (M−1); 1H NMR (400 MHz, D2O): δ 6.96 (s, 1H), 5.29 (d, J=5.2 Hz, 1H), 4.48 (m, 2H), 3.73-3.35 (m, 6H), 1.36 (s, 3H), 1.35 (s, 3H).
Workup
- customthe reaction mixture was quenched with EtOH
- concentrationconcentrated in vacuo
- customThe crude residue was purified by reverse phase prep HPLC (XSelect CSH, 30×100 mm, 5 μm, C18 column; ACN-water with 0.1% formic acid modifier, 60 mL/min)
Sources & evidence
- ORD record
- ord-9296979589d04ea89d1b8cad09783686
- Source dataset
- uspto-grants-2015_11
- Patent number
- US09174978B2
Reaction notes
Loading…